Fetal Diagnosis and Therapy
Massoud M. · Chollet M. · Cabet S. · Butin M. · Mekki Y. · Lina-Granade G. · Fichez A. · Attia J. · Ville D. · Guibaud L.
Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Rent via DeepDyve
Unlimited fulltext viewing of this article
Organize, annotate and mark up articles
Printing and downloading restrictions apply
Start free trial
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Introduction
Our objective was to evaluate the outcome of fetuses with first and second-trimester fetal cytomegalovirus infection (CMVi) according to prenatal imaging patterns, especially fetuses presenting with mild imaging features (MF), being currently of uncertain prognosis.
Material and Methods
Among a retrospective study on 415 suspected CMVi cases, 59 cases were confirmed CMVi.
Among prenatal imaging features, microcephaly, cortical disorder and cerebellar hypoplasia as well as severe IUGR and fetal hydrops were considered as severe imaging features (SF). Others imaging features were considered as mild imaging features (MF).Postnatal outcome was classified as "normal outcome", “mild sequelae” characterized mainly by sensorineural disorder (SND) and “severe sequelae” characterized by cognitive impairment.
Results
Only first-trimester (T1) and second-trimester (T2) CMVi cases were included in our study (n=49) since all third-trimester cases (n=10) had normal imaging and outcome.
Sixteen fetuses had normal prenatal imaging and normal outcome , except one showing SND.
Abnormal ultrasound findings were present in 33 fetuses, including SF noted in 16 fetuses, related exclusively to first trimester CMVi and 17 fetuses with MF (13 during first trimester and 4 during second trimester).
Termination of pregnancy (TOP) was performed in 18 cases. Twelve first-trimester infected fetuses presented SF, whereas 6 fetuses (T1: n=5, T2: n=1) presented isolated MF. Four foetal deaths were encountered.
Live-born babies with abnormal imaging included 10 foetus with MF and one with SF. Among the 10 live babies with isolated MF, SND was encountered in 5 cases, whereas 5 children demonstrated normal outcome. Overall, 50% of our babies showing MF suffered from SND. No case of cognitive disorders were reported in babies showing only MF.
Conclusion
SF were encountered only in first-trimester CMVi and should be distinguished from MF. Among our 10 live babies with prenatal MF following first or second-trimester infection, 50% showed SND whereas none presented severe sequelae. In 16 foetuses displaying normal foetal imaging, SND was encountered in one first-trimester case (6%).
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Comments (0)